Developer docs
API playgroundTry for free, no card

Search company profiles

Palisade Bio

Full company profile

uuid0000g2f

Namestring
Palisade Bio
Legal namestring
Palisade Bio, Inc.
Websiteurl
palisadebio.com
Company typeenum
Public
Founded yearint
2011
Descriptiontext

Palisade Bio, Inc. (NASDAQ: PALI) is a clinical-stage biopharmaceutical company developing oral therapies for inflammatory bowel disease (IBD). Founded in 2011 as Leading BioSciences and restructured in April 2021 via a reverse merger with Seneca Biopharma, the company is incorporated in Delaware with registered offices in Carlsbad, California and operational offices in Denver, Colorado, and operates with a sub-10-employee team. The lead asset, PALI-2108, is a once-daily oral PDE4 inhibitor prodrug designed for selective bioactivation in the ileum and colon, targeting moderate-to-severe ulcerative colitis (UC), Crohn's disease (CD), and fibrostenotic Crohn's disease, the last being a population with particularly limited therapeutic options. The U.S. patient populations cited are approximately 1.95 million for UC and 1.63 million for CD, against current IBD market sizes of roughly $7.7 billion (UC) and $8 billion (CD).

The company's core technology is the proprietary PDE4 Prodrug Platform, which produces a colon-selective prodrug with approximately a 6-fold tissue-to-plasma exposure ratio, slower local release, lower peak plasma concentration, and a longer half-life than traditional PDE4 inhibitors. The design is intended to reduce systemic GI and CNS side effects and to enable once-daily dosing versus the twice-daily regimens required by apremilast and roflumilast. Reported clinical results include 100% clinical response (5/5 patients) and 40% remission in a Phase 1b UC study within seven days, 62.8% mean reduction in modified Mayo score, and 47.5% reduction in SES-CD with 40% endoscopic response/remission in fibrostenotic Crohn's disease, with 89 patients treated and no serious adverse events in the Phase 1a program. In June 2026 FDA cleared the IND for PALI-2108, enabling a global Phase 2 ASCENTRA-UC trial of approximately 204 patients across two dose levels (15 mg and 30 mg), with primary efficacy results anticipated in the second half of 2027. Composition-of-matter patents have been granted in Japan (protection to 2041) and Canada.

Palisade Bio is pre-revenue and operates a traditional clinical-stage biotech model: spending on R&D with no product sales and no licensing revenue disclosed, generating $0 today against approximately $11.45 million of trailing-twelve-month negative EBITDA. Following the October 2025 $138 million public offering led by B Group Capital and Columbia Threadneedle Investments, the company held approximately $133 million in cash, providing three to four years of development runway. The go-to-market posture is therefore oriented around investor relations, healthcare-conference participation (TD Cowen, Jefferies, Leerink, Piper Sandler, Needham), scientific congresses (DDW, ECCO, Crohn's & Colitis Congress), and SEC filings rather than commercial sales channels, with the company's reported market capitalization in the $281–301 million range as of June 2026.

Short descriptiontext

Palisade Bio is a clinical-stage biopharmaceutical company developing PALI-2108, a once-daily oral PDE4 inhibitor prodrug with colon-selective bioactivation for moderate-to-severe ulcerative colitis and Crohn's disease, including fibrostenotic Crohn's disease.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersDenver, United States
HQ citystring
Denver
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
inflammatory bowel disease therapy, PDE4 inhibitor drugs, clinical-stage biopharmaceutical, oral prodrug platform, gastrointestinal therapeutics
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Inflammatory Bowel Disease Therapeutics
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Drug Development and Commercialization
TypeOne Time License
Description

Palisade Bio is a pre-revenue clinical-stage biopharmaceutical company. The company is developing PALI-2108 through clinical trials with the goal of obtaining FDA approval and commercializing the therapy for inflammatory bowel disease. Revenue will be generated through product sales if the drug receives regulatory approval.

palisadebio.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Palisade Bio is a clinical-stage biopharmaceutical company developing PALI-2108, a once-daily oral PDE4 inhibitor prodrug designed for selective bioactivation in the ileum and colon to treat inflammatory bowel disease, including ulcerative colitis and Crohn's disease. The company's pipeline is anchored by this lead candidate built on a proprietary PDE4 Prodrug Platform that targets localized drug activation to improve tolerability and pharmacology versus traditional systemic PDE4 inhibitors.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • 100% clinical response achieved in Phase 1b ulcerative colitis trial (5/5 patients)
+6 more records
Product overview1 text field

Palisade Bio is a clinical-stage biopharmaceutical company advancing targeted oral therapies for inflammatory and fibrotic diseases. The company's portfolio centers on PALI-2108, a once-daily oral PDE4 inhibitor prodrug designed for selective bioactivation in the ileum and colon. The technology is built on the proprietary PDE4 Prodrug Platform, which differentiates traditional PDE4 inhibitors through colon-targeted delivery that improves pharmacokinetics, enhances tolerability by reducing GI side effects, and enables once-daily dosing. The company is advancing toward Phase 2 clinical studies in ulcerative colitis and Crohn's disease.

Product and service2 records
1PALI-2108
CategoryInvestigational drug candidate / biopharmaceutical product
Description

A once-daily oral PDE4 inhibitor prodrug designed to be selectively bioactivated in the ileum and colon for targeted treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Currently in Phase 2 clinical development following FDA IND clearance in June 2026.

2PDE4 Prodrug Platform
CategoryDrug discovery and delivery technology platform
Description

A proprietary technology platform leveraging novel prodrug design to enhance the pharmacology of PDE4 inhibitors, enabling localized delivery in the GI tract with improved tolerability and once-daily dosing potential. Underpins the development of PALI-2108 and serves as the foundation for future pipeline expansion.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
1PSI (Contract Research Organization)
Strategic tierCoreTypeImplementation/ SI/ Consulting PartnerAnnounced on2026-06-29
Description

Partnered with PSI as the contract research organization to manage execution of the global ASCENTRA-UC Phase 2 clinical trial. PSI will manage trial execution across North America and Europe for approximately 204 patients.

morningstar.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-02
Description

Entered into a master services agreement with Iterative Health (also referred to as Iterative Scopes) to assist with patient enrollment for Phase 2 clinical trials. Iterative Health affiliate invested $3 million through purchase of 1,536,885 shares at $1.952 per share (five-day Nasdaq average). The partnership is designed to help accelerate patient recruitment for the ASCENTRA-UC trial of PALI-2108.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-07
Description

Received strategic equity investment of up to $500,000 from the Crohn's & Colitis Foundation's IBD Ventures program to support clinical development of PALI-2108 for fibrostenotic Crohn's disease and ulcerative colitis. This represents an endorsement of the company's targeted gut-restricted PDE4 inhibitor approach.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

J&J markets Stelara and Tremfya in IBD and is the entrenched share leader in moderate-to-severe UC/CD, defining the standard-of-care that PALI-2108 must differentiate against in Phase 2.

TypeBroad incumbent
Description

Lilly is developing mirikizumab (Omvoh) for UC/CD and has been an aggressive acquirer of emerging IBD assets, making it a credible large-pharma comparator and likely strategic counterparty.

TypeEmerging player
Description

Chemomab is a clinical-stage biotech developing therapeutics for inflammatory and fibrotic diseases, overlapping with Palisade's fibrostenotic CD focus; Palisade's CMO previously served as VP of Corporate Development at Chemomab.

TypeBroad incumbent
Description

AbbVie's Skyrizi and Rinvoq are leading IBD biologics/oral therapies; Palisade's regulatory lead (Daniel Larkins) and CMC head both came from AbbVie, and AbbVie is the most likely partner/acquirer for differentiated oral IBD assets.

TypeBroad incumbent
Description

Pfizer markets etrasimod (Velsipity) for UC and acquired Arena Pharmaceuticals for its IBD pipeline, making it a leading commercial comparator for oral IBD therapies targeting the same gastroenterology prescribers.

TypeBroad incumbent
Description

Takeda markets Entyvio (vedolizumab) for UC/CD and is one of the largest GI-focused commercial organizations globally, making it directly comparable on go-to-market dynamics for an oral IBD asset.

TypeBroad incumbent
Description

Amgen markets Otezla (apremilast), the leading oral PDE4 inhibitor, establishing clinical and commercial precedence for the PDE4 mechanism that PALI-2108 is designed to improve upon via colon-selective bioactivation.

8Bristol Myers Squibb
TypeBroad incumbent
Description

BMS markets Zeposia (ozanimod), an oral S1P modulator for UC, and Palisade's VP of Clinical Development (James Izanec) previously led registrational programs at BMS, making it a comparable commercial and a likely strategic party.

TypeDirect peer
Description

Landos is a clinical-stage biotech developing oral therapeutics for IBD and other inflammatory diseases, directly comparable in stage, modality (oral small molecule), and therapeutic focus; Palisade's Head of Clinical Operations previously led clinical operations at Landos.

10Morphic Holding
TypeDirect peer
Description

Morphic developed oral α4β7 integrin inhibitors for IBD, directly comparable as a clinical-stage biotech advancing an oral, gut-targeted small molecule for UC; Eli Lilly acquired Morphic in 2024, illustrating the acquirer pathway.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds13 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors17 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Palisade Bio

Inflammatory Bowel Disease Therapeuticspalisadebio.com

Palisade Bio is a clinical-stage biopharmaceutical company developing PALI-2108, a once-daily oral PDE4 inhibitor prodrug with colon-selective bioactivation for moderate-to-severe ulcerative colitis and Crohn's disease, including fibrostenotic Crohn's disease.

What Palisade Bio does

Palisade Bio, Inc. (NASDAQ: PALI) is a clinical-stage biopharmaceutical company developing oral therapies for inflammatory bowel disease (IBD). Founded in 2011 as Leading BioSciences and restructured in April 2021 via a reverse merger with Seneca Biopharma, the company is incorporated in Delaware with registered offices in Carlsbad, California and operational offices in Denver, Colorado, and operates with a sub-10-employee team. The lead asset, PALI-2108, is a once-daily oral PDE4 inhibitor prodrug designed for selective bioactivation in the ileum and colon, targeting moderate-to-severe ulcerative colitis (UC), Crohn's disease (CD), and fibrostenotic Crohn's disease, the last being a population with particularly limited therapeutic options. The U.S. patient populations cited are approximately 1.95 million for UC and 1.63 million for CD, against current IBD market sizes of roughly $7.7 billion (UC) and $8 billion (CD).

The company's core technology is the proprietary PDE4 Prodrug Platform, which produces a colon-selective prodrug with approximately a 6-fold tissue-to-plasma exposure ratio, slower local release, lower peak plasma concentration, and a longer half-life than traditional PDE4 inhibitors. The design is intended to reduce systemic GI and CNS side effects and to enable once-daily dosing versus the twice-daily regimens required by apremilast and roflumilast. Reported clinical results include 100% clinical response (5/5 patients) and 40% remission in a Phase 1b UC study within seven days, 62.8% mean reduction in modified Mayo score, and 47.5% reduction in SES-CD with 40% endoscopic response/remission in fibrostenotic Crohn's disease, with 89 patients treated and no serious adverse events in the Phase 1a program. In June 2026 FDA cleared the IND for PALI-2108, enabling a global Phase 2 ASCENTRA-UC trial of approximately 204 patients across two dose levels (15 mg and 30 mg), with primary efficacy results anticipated in the second half of 2027. Composition-of-matter patents have been granted in Japan (protection to 2041) and Canada.

Palisade Bio is pre-revenue and operates a traditional clinical-stage biotech model: spending on R&D with no product sales and no licensing revenue disclosed, generating $0 today against approximately $11.45 million of trailing-twelve-month negative EBITDA. Following the October 2025 $138 million public offering led by B Group Capital and Columbia Threadneedle Investments, the company held approximately $133 million in cash, providing three to four years of development runway. The go-to-market posture is therefore oriented around investor relations, healthcare-conference participation (TD Cowen, Jefferies, Leerink, Piper Sandler, Needham), scientific congresses (DDW, ECCO, Crohn's & Colitis Congress), and SEC filings rather than commercial sales channels, with the company's reported market capitalization in the $281–301 million range as of June 2026.

Palisade Bio firmographics

Firmographics
Name
Palisade Bio
Legal name
Palisade Bio, Inc.
Website
https://palisadebio.com
Company type
Public
Founded year
2011
Operating status
Operating
Headcount range
11–50 employees
Short description
Palisade Bio is a clinical-stage biopharmaceutical company developing PALI-2108, a once-daily oral PDE4 inhibitor prodrug with colon-selective bioactivation for moderate-to-severe ulcerative colitis and Crohn's disease, including fibrostenotic Crohn's disease.
Ownership category
akta.pro rank

Where Palisade Bio is headquartered

Location

Headquarters

HQ city
Denver
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Palisade Bio business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Drug Development and Commercialization: Palisade Bio is a pre-revenue clinical-stage biopharmaceutical company. The company is developing PALI-2108 through clinical trials with the goal of obtaining FDA approval and commercializing the therapy for inflammatory bowel disease. Revenue will be generated through product sales if the drug receives regulatory approval.

Go-to-market motion1 record

Marketing channels5 records

Palisade Bio product offering

Product offering

Core offering

Palisade Bio is a clinical-stage biopharmaceutical company developing PALI-2108, a once-daily oral PDE4 inhibitor prodrug designed for selective bioactivation in the ileum and colon to treat inflammatory bowel disease, including ulcerative colitis and Crohn's disease. The company's pipeline is anchored by this lead candidate built on a proprietary PDE4 Prodrug Platform that targets localized drug activation to improve tolerability and pharmacology versus traditional systemic PDE4 inhibitors.

Product overview

Palisade Bio is a clinical-stage biopharmaceutical company advancing targeted oral therapies for inflammatory and fibrotic diseases. The company's portfolio centers on PALI-2108, a once-daily oral PDE4 inhibitor prodrug designed for selective bioactivation in the ileum and colon. The technology is built on the proprietary PDE4 Prodrug Platform, which differentiates traditional PDE4 inhibitors through colon-targeted delivery that improves pharmacokinetics, enhances tolerability by reducing GI side effects, and enables once-daily dosing. The company is advancing toward Phase 2 clinical studies in ulcerative colitis and Crohn's disease.

Differentiator

Problem solved

Functional benefit

Products and services

  • PALI-2108 A once-daily oral PDE4 inhibitor prodrug designed to be selectively bioactivated in the ileum and colon for targeted treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Currently in Phase 2 clinical development following FDA IND clearance in June 2026.
  • PDE4 Prodrug Platform A proprietary technology platform leveraging novel prodrug design to enhance the pharmacology of PDE4 inhibitors, enabling localized delivery in the GI tract with improved tolerability and once-daily dosing potential. Underpins the development of PALI-2108 and serves as the foundation for future pipeline expansion.

Quantifiable outcome

  • 100% clinical response achieved in Phase 1b ulcerative colitis trial (5/5 patients)
  • +6 more outcomes

Companies that use Palisade Bio

Customer profile

Segments1 record

Ideal customer profiles2 records

Palisade Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Palisade Bio partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • PSI (Contract Research Organization)coreImplementation/ SI/ Consulting Partner · 29 June 2026Partnered with PSI as the contract research organization to manage execution of the global ASCENTRA-UC Phase 2 clinical trial. PSI will manage trial execution across North America and Europe for approximately 204 patients.
  • Iterative Health / Iterative ScopescoreStrategic or Co-development Partner · 2 April 2026Entered into a master services agreement with Iterative Health (also referred to as Iterative Scopes) to assist with patient enrollment for Phase 2 clinical trials. Iterative Health affiliate invested $3 million through purchase of 1,536,885 shares at $1.952 per share (five-day Nasdaq average). The partnership is designed to help accelerate patient recruitment for the ASCENTRA-UC trial of PALI-2108.
  • Crohn's & Colitis FoundationcoreStrategic or Co-development Partner · 7 January 2026Received strategic equity investment of up to $500,000 from the Crohn's & Colitis Foundation's IBD Ventures program to support clinical development of PALI-2108 for fibrostenotic Crohn's disease and ulcerative colitis. This represents an endorsement of the company's targeted gut-restricted PDE4 inhibitor approach.

Scale indicators8 records

Recent moves7 records

Expansion highlights6 records

Palisade Bio competitors and assessment

Company assessment

Broad incumbents

  • Johnson & Johnson: J&J markets Stelara and Tremfya in IBD and is the entrenched share leader in moderate-to-severe UC/CD, defining the standard-of-care that PALI-2108 must differentiate against in Phase 2.
  • Eli Lilly: Lilly is developing mirikizumab (Omvoh) for UC/CD and has been an aggressive acquirer of emerging IBD assets, making it a credible large-pharma comparator and likely strategic counterparty.
  • AbbVie: AbbVie's Skyrizi and Rinvoq are leading IBD biologics/oral therapies; Palisade's regulatory lead (Daniel Larkins) and CMC head both came from AbbVie, and AbbVie is the most likely partner/acquirer for differentiated oral IBD assets.
  • Pfizer: Pfizer markets etrasimod (Velsipity) for UC and acquired Arena Pharmaceuticals for its IBD pipeline, making it a leading commercial comparator for oral IBD therapies targeting the same gastroenterology prescribers.
  • Takeda: Takeda markets Entyvio (vedolizumab) for UC/CD and is one of the largest GI-focused commercial organizations globally, making it directly comparable on go-to-market dynamics for an oral IBD asset.
  • Amgen (Otezla/apremilast): Amgen markets Otezla (apremilast), the leading oral PDE4 inhibitor, establishing clinical and commercial precedence for the PDE4 mechanism that PALI-2108 is designed to improve upon via colon-selective bioactivation.
  • Bristol Myers Squibb: BMS markets Zeposia (ozanimod), an oral S1P modulator for UC, and Palisade's VP of Clinical Development (James Izanec) previously led registrational programs at BMS, making it a comparable commercial and a likely strategic party.

Emerging players

  • Chemomab Therapeutics: Chemomab is a clinical-stage biotech developing therapeutics for inflammatory and fibrotic diseases, overlapping with Palisade's fibrostenotic CD focus; Palisade's CMO previously served as VP of Corporate Development at Chemomab.

Direct peers

  • Landos Biopharma: Landos is a clinical-stage biotech developing oral therapeutics for IBD and other inflammatory diseases, directly comparable in stage, modality (oral small molecule), and therapeutic focus; Palisade's Head of Clinical Operations previously led clinical operations at Landos.
  • Morphic Holding: Morphic developed oral α4β7 integrin inhibitors for IBD, directly comparable as a clinical-stage biotech advancing an oral, gut-targeted small molecule for UC; Eli Lilly acquired Morphic in 2024, illustrating the acquirer pathway.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Palisade Bio social profiles

Digital presence

Palisade Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Palisade Bio leadership team

Management profile

Number of profiles

Profiles13 records

Palisade Bio funding detail

Funding detail

Funding overview

Funding rounds13 records

Investors17 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Palisade Bio M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Palisade Bio

What does Palisade Bio do?

Palisade Bio is a clinical-stage biopharmaceutical company developing PALI-2108, a once-daily oral PDE4 inhibitor prodrug designed for selective bioactivation in the ileum and colon to treat inflammatory bowel disease, including ulcerative colitis and Crohn's disease. The company's pipeline is anchored by this lead candidate built on a proprietary PDE4 Prodrug Platform that targets localized drug activation to improve tolerability and pharmacology versus traditional systemic PDE4 inhibitors.

Is Palisade Bio a public or private company?

Palisade Bio is a public company. It is classified as public and is currently operating.

When was Palisade Bio founded?

Palisade Bio was founded in 2011. It employs 11 to 50 people.

Where is Palisade Bio based?

Palisade Bio is headquartered in Denver, United States, in the North America region.

How does Palisade Bio make money?

One revenue line is on record: drug Development and Commercialization.

Who are Palisade Bio's main competitors?

Broad incumbents on record are Johnson & Johnson, Eli Lilly, AbbVie, Pfizer, Takeda, Amgen (Otezla/apremilast) and Bristol Myers Squibb. Chemomab Therapeutics is listed as an emerging player. Direct peers are Landos Biopharma and Morphic Holding.

Does Palisade Bio have an API?

No public API is recorded for Palisade Bio.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewPalisade Bio, Inc. Stock 12‑Month Price Target Raised to $9.4, Implies 898% UpsideAnalysts' average price target for Palisade Bio, Inc. rose to $9.4 from $9, implying about 898% upside from the Nov. 18 closing price. The consensus remains a Buy across 10 analysts, with targets ranging from $5 to $16 per share.TradingViewPalisade Bio, Inc. Stock 12‑Month Price Target Cut to $9, Implies 696% UpsideAnalysts' average price target for Palisade Bio, Inc. fell from $10 to $9, with forecasts ranging from $5 to $16 per share. Based on the Nov. 10 closing price, the target implies about 696% upside. The consensus rating remains Buy across 11 analysts.TradingViewPiper Sandler maintains Palisade Bio at Overweight, lowers price target to $16 from $25Piper Sandler maintained Palisade Bio at Overweight and lowered its price target to $16 from $25, a 36% decrease. The target implies an upside of 1315.9% from the Nov 10 close of $1.13.Seeking AlphaPalisade: Initiating 'Buy' On PALI-2108 UC Study Start And Differentiated PDE4 InhibitorAn analyst initiated Palisade Bio with a Buy rating on its PDE4 inhibitor prodrug PALI-2108 for inflammatory bowel diseases. The phase 2b ASCENTRA-UC trial for ulcerative colitis has begun dosing, with 12-week topline results expected in Q4 2027. Expansion opportunities include a phase 2a trial in Crohn's disease starting Q1 2027.MarketBeatPalisade Bio, Inc. (NASDAQ:PALI) Stock Has Average Target Price of $9.29Palisade Bio has an average analyst rating of Buy with a $9.29 price target. The stock opened at $1.20, and the company reported a loss of $0.05 per share for the quarter, meeting estimates. Analysts expect a -0.22 EPS for the current year.American Banking and Market NewsAnalyzing Theravance Biopharma (NASDAQ:TBPH) & Palisade Bio (NASDAQ:PALI)Palisade Bio beats Theravance Biopharma on 8 of 15 factors, including analyst ratings and valuation. Palisade has a consensus target price of $9.29 (673.81% upside) versus Theravance's $19.40 (13.92% upside). Palisade's beta is 1.61, while Theravance's is 0.25.The future of tradingPalisade Bio Awards 787,300 Restricted Stock Units to General Counsel Julien CapersPalisade Bio granted General Counsel and Corporate Secretary Julien E. Capers 787,300 common shares on Oct. 19, 2026. The award was published via EDGAR on Oct. 21, 2026.American Banking and Market NewsNexentis Technologies (NASDAQ:NXTS) & Palisade Bio (NASDAQ:PALI) Head to Head AnalysisPalisade Bio beats Nexentis Technologies on 9 of 14 factors, including a stronger analyst consensus and higher upside. Palisade Bio's consensus price target is $9.29, implying a 549.35% upside, while Nexentis Technologies has a sell rating. Palisade Bio is also more affordable with a lower price-to-earnings ratio.MarketBeatPalisade Bio (NASDAQ:PALI) Downgraded by Wall Street Zen to "Sell"Wall Street Zen downgraded Palisade Bio from 'hold' to 'sell' in a research note. The company's consensus rating remains 'Buy' with an average price target of $9.29, and it reported a loss of $0.05 per share for the quarter. Analysts expect a fiscal-year EPS of -$0.22.American Banking and Market NewsPalisade Bio (NASDAQ:PALI) Rating Lowered to Sell at Wall Street ZenWall Street Zen downgraded Palisade Bio from hold to sell. The stock opened at $1.41, with a consensus rating of Buy and a price target of $9.29. Analysts expect a loss of $0.22 per share for the current year.